Tata India Pharma & Healthcare Fund-Regular Plan-Growth
💡 Why Pick This Fund? Quantitative Strengths & Watch-outs
- Outperformed category benchmark in 69% of historical 3-year rolling periods.
- Strong capital defense: downside capture of 66% limits losses during market corrections.
- Generated +7.1% annualized alpha (excess return) over its benchmark.
- Over 11 years of operational history across different market cycles.
- Equities carry market risk; returns fluctuate and recommended investment horizon is 5+ years.
Key Statistics vs Category Median
Trailing Returns Comparison
| Period | Fund Return | Category Median | Difference |
|---|---|---|---|
| 1 Month | +7.52% | +6.32% | +1.20% |
| 3 Months | -1.00% | -0.20% | -0.80% |
| 6 Months | +6.63% | +5.98% | +0.65% |
| 1 Year | +9.76% | +3.90% | +5.86% |
| 3 Years CAGR | +17.37% | +13.23% | +4.14% |
| 5 Years CAGR | +14.23% | +10.72% | +3.51% |
| 7 Years CAGR | +20.74% | +15.35% | +5.39% |
| 10 Years CAGR | +13.96% | +14.26% | -0.30% |
| Since Inception | +11.78% | - | - |
📈 Monthly SIP vs Bank Fixed Deposit (FD) Replay
See how a regular monthly SIP in Tata India Pharma & Healthcare Fund compares against a standard 7.0% p.a. Bank Fixed Deposit.
Calendar Year Returns
| Year | Fund | Category Median | Gap |
|---|---|---|---|
| 2026 | +11.43% | +4.03% | +7.40% |
| 2025 | -4.92% | +1.43% | -6.35% |
| 2024 | +40.40% | +20.41% | +19.99% |
| 2023 | +36.58% | +30.70% | +5.88% |
| 2022 | -8.04% | +1.66% | -9.70% |
| 2021 | +19.07% | +30.31% | -11.24% |
| 2020 | +64.38% | +13.54% | +50.84% |
| 2019 | +5.51% | +7.11% | -1.60% |
| 2018 | -2.62% | -5.94% | +3.32% |
| 2017 | +4.65% | +39.22% | -34.57% |
| 2016 | -14.65% | +4.10% | -18.75% |
Daily Rolling Returns Summary
| Rolling Window | Minimum | Average | Median | Maximum | % Positive | % Beating Proxy |
|---|---|---|---|---|---|---|
| 1-Year Rolling | -18.70% | +14.69% | +7.18% | +73.72% | 66.8% | 54.1% |
| 3-Year Rolling | -5.18% | +16.44% | +19.31% | +28.38% | 88.4% | 69.1% |
| 5-Year Rolling | +7.47% | +16.94% | +14.85% | +29.76% | 100.0% | 60.3% |
Risk Profile & Deepest Drawdowns
Deepest Market Corrections (Depth >= 10%)
| Peak Date | Trough Date | Fall Depth | Months to Bottom | Recovery Period |
|---|---|---|---|---|
| 2016-02-01 | 2018-06-05 | -21.9% | 28 months | 21 months |
| 2020-02-19 | 2020-03-23 | -18.6% | 1 months | 1 months |
| 2021-09-15 | 2022-06-17 | -18.2% | 9 months | 13 months |
Portfolio & Asset Allocation
Statutory Asset Allocation Mandate (SEBI / SID)
| Instrument Category | Permitted Allocation Range |
|---|---|
| Equity & equity related instruments of companies in the Pharma & Healthcare Sectors^ 80% - 100%, Other Equity/Equity related instruments 0% - 20%, Money Market Instruments, other liquid instruments**, gold and/or silver instruments/ETF, InvITs as permitted by SEBI 0% - 20%. The scheme may invest in another scheme under the same asset management company or any other mutual fund without charging any fees, provided that aggregate inter-scheme investment made by all schemes under the same management or in schemes under the management of any other asset management company shall not exceed 5% of the net asset value of the mutual fund. Such investments shall be made in the schemes which are permitted by SEBI from time to time. ** Other liquid instruments include cash, bank deposits with Scheduled Commercial Banks, Government Securities, Treasury bills, Repo on Government securities and any other instruments as specified by the SEBI. Units of Equity Mutual funds will be considered under allocation for Equity and Equity related instruments | Per Scheme Mandate |
Investment Objective & Strategy
The investment objective of the scheme is to seek long term capital appreciation by investing atleast 80% of its net assets in equity/equity related instruments of the companies in the pharma & healthcare sectors in India.However, there is no assurance or guarantee that the investment objective of the Scheme will be achieved.The Scheme does not assure or guarantee any returns.
ℹ️ Detailed monthly stock-level holdings for this scheme are updated periodically from asset management company statutory disclosures.
Fund Size Position
Currently managing Rs 1,589 cr (AMFI Daily Fund AUM as of 2026-11-11). Positioned as comfortable relative to Sectoral / Thematic schemes.
Fund Management
Cost & Capital Gains Taxation
From April 2026 the total expense ratio includes brokerage, transaction costs and statutory levies on top of the base fee.
Equity-oriented schemes: 20% short-term capital gains tax if sold within 12 months; 12.5% long-term capital gains tax on gains exceeding ₹1.25 lakh per financial year when held for more than 12 months.
Closest Sectoral / Thematic Peers by Rank
| Scheme | Score | 3Y Return | Expense | Downside | Fund Size | Compare |
|---|---|---|---|---|---|---|
| Aditya Birla Sun Life Manufacturing Equity Fund | 6.0 | +19.80% | 2.32% | 100.0% | Rs 1,407 cr | Compare → |
| Kotak Manufacture in India Fund | 7.8 | +19.59% | 2.06% | 99.2% | Rs 3,217 cr | Compare → |
| ITI Pharma and Healthcare Fund | 6.6 | +18.46% | 2.57% | 71.7% | Rs 283 cr | Compare → |
| Axis Innovation Fund | 6.4 | +17.90% | 2.27% | 81.1% | Rs 1,386 cr | Compare → |
| Aditya Birla Sun Life Special Opportunities Fund | 7.1 | +18.81% | 2.26% | 78.6% | Rs 1,475 cr | Compare → |
Frequently Asked Questions about Tata India Pharma & Healthcare Fund
What is the expense ratio of Tata India Pharma & Healthcare Fund?
Tata India Pharma & Healthcare Fund has a total expense ratio (TER) of 2.4% with a base expense ratio of 1.79%, compared to the Sectoral / Thematic category median of 2.52%.
Who manages Tata India Pharma & Healthcare Fund?
Tata India Pharma & Healthcare Fund is managed by Rajat Srivastava (tenure: 2.2 years since 2024-09-16).
What are the historical returns of Tata India Pharma & Healthcare Fund?
Tata India Pharma & Healthcare Fund delivered a 3-year CAGR of 17.37% and a 5-year CAGR of 14.23%. Its 1-year return stands at +9.76%.
How large is Tata India Pharma & Healthcare Fund?
Tata India Pharma & Healthcare Fund manages assets of Rs 1,589 cr, placing it in the 'comfortable' size band relative to Sectoral / Thematic peers.
How is Tata India Pharma & Healthcare Fund scored on MFIQ?
Tata India Pharma & Healthcare Fund holds an MFIQ Score of 6.2/10 (Average), based on a category percentile composite across returns, risk, consistency, and cost.
How risky is Tata India Pharma & Healthcare Fund?
Tata India Pharma & Healthcare Fund has an official SEBI riskometer rating of Very High. Over the analyzed period, its annualized standard deviation is 13.37% with a maximum historical drawdown of -21.94%.